東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

A study of cell death pathways and i...

Guerriero, Jennifer Lynn.

Linked to FindBook

Google Book

Amazon

博客來

A study of cell death pathways and innate immunity in cancer chemotherapy.

Record Type:	Language materials, printed : Monograph/item
Title/Author:	A study of cell death pathways and innate immunity in cancer chemotherapy./
Author:	Guerriero, Jennifer Lynn.
Description:	101 p.
Notes:	Source: Dissertation Abstracts International, Volume: 71-10, Section: B, page: 5879.
Contained By:	Dissertation Abstracts International71-10B.
Subject:	Biology, Cell. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3422816
ISBN:	9781124226644

A study of cell death pathways and innate immunity in cancer chemotherapy.
Guerriero, Jennifer Lynn.

A study of cell death pathways and innate immunity in cancer chemotherapy. - 101 p.

Source: Dissertation Abstracts International, Volume: 71-10, Section: B, page: 5879.

Thesis (Ph.D.)--State University of New York at Stony Brook, 2010.

Dysregulation of apoptosis is associated with the development of human cancer and resistance to anti-cancer therapy. The ultimate goal of cancer treatment is to selectively induce cancer cell death and to overcome drug resistance. A deeper understanding of how chemotherapy affects tumor cell death is needed in order to develop strategically designed anti-cancer agents. An athymic mouse xenograft tumor system was established utilizing genetically defined cells that are deficient in apoptosis to examine the involvement of multiple forms of cell death induced by a DNA alkylating agent commonly used in chemotherapy. In response to DNA alkylating damage, although apoptosis facilitates a more rapid tumor regression, it is dispensable for complete tumor regression as other forms of cell death such as sporadic necrosis, senescence, autophagy, and mitotic catastrophe are activated. Of these, sporadic necrosis plays a fundamental role in tumor clearance by stimulating the innate immune response in a manner that is dependent upon the high mobility group box 1 (HMGB1) protein. HMGB1 is released from necrotic cells and once outside the cell, it acts as a damage-associated molecular pattern (DAMP) molecule to alert the host of damage by triggering immune responses. Interestingly, while DNA alkylating therapy leads to complete tumor regression in this mouse model, tumors deficient in HMGB1 fail to fully regress. The HMGB1-deficient tumors have an attenuated ability to recruit innate immune cells including macrophages, neutrophils, and natural killer (NK) cells into the treated tumor tissue. Cytokine array analysis reveals that while DNA alkylating treatment leads to suppression of pro-tumor cytokines such as IL-4, IL-10, and IL-13, loss of HMGB1 leads to elevated levels of these cytokines upon treatment. Suppression of innate immunity and HMGB1 using neutralizing antibodies leads to a failure in tumor regression. Taken together, these results indicate that DNA alkylating therapy can induce multiple forms of cell death and extracellular release of cellular contents such as HMGB1, which in turn leads to the activation of innate immunity and tumor regression.

ISBN: 9781124226644Subjects--Topical Terms:

1017686
Biology, Cell.

A study of cell death pathways and innate immunity in cancer chemotherapy.
LDR:03296nam 2200337 4500 001 1403171
005 20111111141820.5
008 130515s2010 ||||||||||||||||| ||eng d
020 $a 9781124226644
035 $a (UMI)AAI3422816
035 $a AAI3422816
040 $a UMI $c UMI
100 1 $a Guerriero, Jennifer Lynn. $3 1682420
245 1 2 $a A study of cell death pathways and innate immunity in cancer chemotherapy.
300 $a 101 p.
500 $a Source: Dissertation Abstracts International, Volume: 71-10, Section: B, page: 5879.
500 $a Adviser: Wei-Xing Zong.
502 $a Thesis (Ph.D.)--State University of New York at Stony Brook, 2010.
520 $a Dysregulation of apoptosis is associated with the development of human cancer and resistance to anti-cancer therapy. The ultimate goal of cancer treatment is to selectively induce cancer cell death and to overcome drug resistance. A deeper understanding of how chemotherapy affects tumor cell death is needed in order to develop strategically designed anti-cancer agents. An athymic mouse xenograft tumor system was established utilizing genetically defined cells that are deficient in apoptosis to examine the involvement of multiple forms of cell death induced by a DNA alkylating agent commonly used in chemotherapy. In response to DNA alkylating damage, although apoptosis facilitates a more rapid tumor regression, it is dispensable for complete tumor regression as other forms of cell death such as sporadic necrosis, senescence, autophagy, and mitotic catastrophe are activated. Of these, sporadic necrosis plays a fundamental role in tumor clearance by stimulating the innate immune response in a manner that is dependent upon the high mobility group box 1 (HMGB1) protein. HMGB1 is released from necrotic cells and once outside the cell, it acts as a damage-associated molecular pattern (DAMP) molecule to alert the host of damage by triggering immune responses. Interestingly, while DNA alkylating therapy leads to complete tumor regression in this mouse model, tumors deficient in HMGB1 fail to fully regress. The HMGB1-deficient tumors have an attenuated ability to recruit innate immune cells including macrophages, neutrophils, and natural killer (NK) cells into the treated tumor tissue. Cytokine array analysis reveals that while DNA alkylating treatment leads to suppression of pro-tumor cytokines such as IL-4, IL-10, and IL-13, loss of HMGB1 leads to elevated levels of these cytokines upon treatment. Suppression of innate immunity and HMGB1 using neutralizing antibodies leads to a failure in tumor regression. Taken together, these results indicate that DNA alkylating therapy can induce multiple forms of cell death and extracellular release of cellular contents such as HMGB1, which in turn leads to the activation of innate immunity and tumor regression.
590 $a School code: 0771.
650 4 $a Biology, Cell. $3 1017686
650 4 $a Health Sciences, Immunology. $3 1017716
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0379
690 $a 0982
690 $a 0992
710 2 $a State University of New York at Stony Brook. $b Molecular and Cellular Biology. $3 1682421
773 0 $t Dissertation Abstracts International $g 71-10B.
790 1 0 $a Zong, Wei-Xing, $e advisor
790 1 0 $a Fleit, Howard B. $e committee member
790 1 0 $a Moll, Ute $e committee member
790 1 0 $a Reich, Nancy $e committee member
790 1 0 $a Crawford, Howard $e committee member
790 $a 0771
791 $a Ph.D.
792 $a 2010
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3422816